Cyclacel Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYCC research report →
About the company
Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development stage, focused on discovering and advancing treatments for various cancers and other diseases involving abnormal cell growth. The company's active drug pipeline includes several promising candidates: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is presently undergoing Phase 1/2 clinical studies for solid tumors and is also being evaluated in combination with venetoclax for patients with chronic lymphocytic leukemia that has recurred or is resistant to previous therapies.
- CEO
- Sing Ee Wong
- IPO
- 2004
- Employees
- 12
- HQ
- Berkeley Heights, NJ, US
Price Chart
- Market Cap
- $10.61M
- P/E
- -1.86
- P/S
- 1.52
- P/B
- 0.86
- EV/EBITDA
- 0.28
- Div Yield
- 0.00%
- Gross Margin
- 18.36%
- Op Margin
- -238.49%
- Net Margin
- -204.20%
- ROE
- -51.20%
- ROIC
- -53.74%
- Revenue
- $747.00K · 1637.21%
- Net Income
- $-2,998,000 · 73.26%
- EPS
- $-6.45 · -374.26%
- Op Income
- $-8,427,000
- FCF YoY
- 40.30%
- 52W High
- $597.60
- 52W Low
- $3.08
- 50D MA
- $8.11
- 200D MA
- $44.19
- Beta
- 0.16
- Avg Volume
- 1.81M
Get TickerSpark's AI analysis on CYCC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 5, 25 | Kua Khai Loon | sell | 19,054 |
| Sep 4, 25 | Yap Kim Choy | other | 186,465 |
| Sep 4, 25 | Yap Kim Choy | other | 186,465 |
| Sep 4, 25 | Kua Khai Loon | other | 186,465 |
| Sep 4, 25 | Kua Khai Loon | other | 186,465 |
| Sep 4, 25 | Ong Yee Lung | other | 186,465 |
| Sep 4, 25 | Ong Yee Lung | other | 186,465 |
| Sep 1, 25 | Ong Yee Lung | other | 0 |
| Jun 20, 25 | Ong Yee Lung | other | 218,000 |
| Jun 20, 25 | Ong Yee Lung | other | 218,000 |
Our CYCC coverage
Recent articles, reports, and earnings notes.
No research on CYCC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CYCC report →Similar companies
Peers in the same neighborhood.